Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2020

View Archived Issues

Ovarian organoids implicate oviducts

iPSC microtissue gives clues to heart disease

Estrogen and dopamine

Identification of a JAK inhibitor selectively targeting GI tissues for inflammatory bowel disease

A new ASK1 inhibitor presenting brain penetration

FDA accepts IND for phase I/II trial of Treadwell's HPK1 inhibitor CFI-402411

Brukinsa receives approval in China for patients with CLL/SLL and MCL

First patient data presented for PF-06804103 antibody-drug conjugate

Rgenix presents monotherapy dose-escalation data from phase I study of RGX-202

Phase II data reported from TreeTopp study of varlitinib plus capecitabine in BTC

FDA gives FSD Pharma permission to submit IND for phase IIa trial of FSD-201 for COVID-19

Ube Industries discloses cyclin-dependent kinase 7 inhibitors

Shanghai Ennova Biopharmaceutical patents neurotrophic tyrosine kinase receptor inhibitors

New MAP4K1 inhibitors discovered at Pfizer

New monobactam compounds presented by Nanjing Sanhome Pharmaceutical

Idorsia Pharmaceuticals identifies new Ox1-R and Ox2-R antagonists

Data questions arise for two major COVID-19 studies

Kezar reports updated phase Ib findings on KZR-616 in SLE

Maxinovel studies MAX-10181 for advanced solid tumors in first-in-human trial

Kadmon begins first-in-human study of KD-033 in metastatic or locally advanced solid tumors

European approval for Braftovi with cetuximab for BRAF V600E-mutant metastatic colorectal cancer

ImmuneOncia begins first-in-human study of IMC-002 for advanced solid tumors and lymphomas

Phase II dose defined in trial of CBL-0137 in patients with solid tumors

Pilot study evaluates DNAJB1-PRKACA peptide vaccine for fibrolamellar hepatocellular carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...